S&P 500 climbs, but Nvidia slip keeps lid on gains
McKesson Corporation's stock reached an all-time high of $864.14, marking a significant milestone for the company. According to InvestingPro data, this represents a slight premium to its Fair Value estimate, with the stock trading near its 52-week high. This achievement reflects a robust 41.96% increase over the past year, underscoring strong investor confidence and positive market performance. The pharmaceutical distribution giant, with a market capitalization of $106.8 billion, has seen steady growth, with its stock price consistently climbing, culminating in this record-breaking high. The impressive year-to-date return of 51.15% highlights McKesson's successful strategies and resilience in a competitive industry, attracting attention from investors and analysts alike. InvestingPro analysis reveals the company maintains a "GREAT" overall financial health score and management has been aggressively buying back shares. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for McKesson and 1,400+ other US equities, offering expert analysis on what truly matters for this healthcare provider.
In other recent news, McKesson Corporation reported its fiscal Q2 2026 earnings, revealing a significant increase in earnings per share (EPS) while slightly missing revenue forecasts. The company posted an EPS of $9.86, exceeding the anticipated $9.04, but reported revenue of $103 billion, which was just below the expected $104.15 billion. Following these results, Leerink Partners raised its price target for McKesson from $850 to $965, maintaining an Outperform rating and highlighting the company's strong performance across all major segments. Similarly, Evercore ISI increased its price target to $1,000 from $825, also maintaining an Outperform rating. Evercore ISI noted the strength in McKesson's North American Pharmaceutical segment, projecting a 7% core adjusted operating income growth for fiscal year 2026. The firm expects a 4-5% growth in the second half of the year compared to 7-11% in the first half. These developments reflect the positive sentiment among analysts regarding McKesson's recent performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.